Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This (5/6-5/10) could be important . Wish all longs the best, we're due.
Let's not forget there is no brain swelling, bleeding or dying from taking Blarcamesine.
That has to be worth something, right?
Psy op shorters are worried that they may lose their hold/control of this board!
Welcome, Tredenwater2, I am your host, Mr. O’Rourke. Welcome to Fantasy Island.
Another great post from ST
----------------------------------------------
First, I believe that most of this data “management” by Missling derives from his character to minimize information in order to minimize risk of assault by the ubiquitous bears
How can any one believe this crap? Are these people under some kind of Misleading spell?
3-71 need another 10-15 year before the clown declares it as another failed drug from his circus...
The Cost of Schizophrenia Exceeds $170 Billion Annually and yet, Anavex Life Sciences could safe the US economy $BILLION$ per year with the approval of Anavex 3-71.
"...n total, the estimated societal lifetime cost per person was $2.38 million, or $89,798 per year lived with schizophrenia. Virtually all of the incremental fiscal burden occurs within the first 35 years after symptom onset, highlighting the importance of early intervention....."
"...Schizophrenia is also a costly disease, with an estimated annual fiscal burden in the US of $173.6 billion..."
https://www.psychiatrist.com/news/weekly-mind-reader-cost-schizophrenia-exceeds-170-billion-annually/#:~:text=In%20total%2C%20the%20estimated%20societal,the%20importance%20of%20early%20intervention.
Good luck and GOD bless,
Looks at the weekend pumping post on this board and ST, these kind of posts are sucking in gullible retailer into this POS and NWBO.
Sorry state of affair, people have so many theories , they all think FDA and big Bios are going after tiny trial Anavex and Misleading is a messiah, who blabbers and fumbles in every CC, a buzzword king.
From ST
----------------
Even more importantly, the EMA has initially reviewed ALL of the data, and decided that they want an application for approval asap. Of course, the EMA may have made a mistake, but I am willing to bet that they are serious professionals
---------------------------------------------------------------------------------------------------
As a person capable of understanding data--and make no mistake, most do not, even if they say they do--I'd rather have it all, but I'm nobody. I hold faith it was withheld to 1) have it vetted to exhaustion by extreme authorities on the matter, 2) maximize secrecy leverage with interested partners who need to bid against each other in an urgent fashion while the company remains under the radar, and/or 3) protection of the company from takeover intentions.
------------------------------------------------------------------------------------------------
IMO, AVXL is working to achieve this level of WW recognition...
We are on a path less traveled but, it is the correct one and we know it. Prayer and hard work and knowledge are our tools. Hang in there.
https://www.acs.org/education/whatischemistry/landmarks/flemingpenicillin.html#:~:text=Penicillin%20heralded%20the%20dawn%20of,them%20but%20wait%20and%20hope.
International Historic Chemical Landmark
Designated November 19, 1999, at the Alexander Fleming Laboratory Museum in London, U.K. Also recognized at the U.S. Department of Agriculture National Center for Agricultural Utilization Research in Peoria, Ill., and the five American pharmaceutical companies that contributed to penicillin production research during WWII: Abbott Laboratories, Lederle Laboratories (now Pfizer, Inc.), Merck & Co., Inc., Chas. Pfizer & Co. Inc. (now Pfizer, Inc.) and E.R. Squibb & Sons (now Bristol-Myers Squibb Company).
Someone asked this question:
“Since you've been following, how did the various allegations consolidate to the lead plaintiff part?”
I provided help to self help. It’s still a case of waiting until 13th May…
“How many drugs are out there that reduce brain atrophy?”
Or fix chromatin remodeling? Or help alleviate insomnia/sleep disturbances from which most CNS conditions come from due to lack of REM sleep? All this and more with NO AE’s or expensive transfusions in clinics!
“Missling playing the brilliant mind, with no clue how it really works. Then indeed you may better give up and sell of.”
Last time I checked he knows exactly how it works. In fact, Kun Jin, ex lead biostatician for the fda knows exactly how it works as well nd chose to join our company. His experience layes with how agencies like to see the data come across in a package. He was most limely responsible for handling Biojunks Acudumab submission which garnered approval.
With our company on the verge of filing an MAA for “full approval” and the Fda’s recent change in Alzheimer’s trial protocol for endpoints I would say he is locked on pretty tight with the people he has in place.
Big time partnership negotiations going on right now imo as we get ready to submit our MAA and soon an NDA. Oh and worrying about competitors making up stories, we should put that to rest with the third party peer reviewed paper due out and day/week, way overdue!
tradeherpete - "What Dr. would have a problem prescribing a safe drug to a CNS patient that will slow their brain shrinkage?"
Yes. Fully agree. I tagged a $15 billion MC price because it's obvious what kind of break through therapy this is. Your right. You can't really put a price on this when everyone after 49 years old needs to preserve their brain from shrinking. Lol. Oh My...
How many drugs are out there that reduce brain atrophy? - ihidfromthex
That right there is worth a $15 billion Market Cap. - bb8675309
What Dr. would have a problem prescribing a safe drug to a CNS patient that will slow their brain shrinkage?
I think more than 15b. It's foolish at this point to try and predict how much but yes, more.
Yes I know a lady who has been in Biogen's test since it started. Then it stopped during covid and then it restarted. She was at 22 on the MMSE scale when she started the test with Biogen. Now yes she recognizes her Husband but not others she knew back then. Still does reasonably well for antiquated memories. Yes ALZ is a terrible disease.
John k9uwa
So this Jonathan Blum is their "Lead Plaintiff" He holds 427 shares of AVXL Stock. He signed the paperwork for the attorney on 3/18/2024. PPS was around $5.25 on March 13th 2024. His total invested in AVXL over 9 months $3,564 plus whatever his broker charged for 5 purchases. If he had sold the 427 shares the day he signed to be Lead Plaintiff he would have received $2,058 for a loss of $1,506 ... No Wonder Korsinsky has been begging daily for a "Lead Plaintiff"
John k9uwa
Below copied from Korsinsky's 3/18/2024 filing.
https://www.courtlistener.com/docket/68337947/blum-v-anavex-life-sciences-corporation/
Case Name Anavex Life Sciences Corp.
Ticker AVXL
Class Period 01-15-2022 to 01-01-2024
Client Name
Jonathan Blum
Date of Transaction Transaction Type Quantity Price per Share
03-18-2022 P 0 $ 12.8800
09-14-2023 P 11 $ 08.1100
11-30-2023 P 155 $ 07.1500
12-03-2023 P 100 $ 07.7400
12-19-2023 P 111 $ 09.8800
12-19-2023 P 50 $ 09.9100
How many drugs are out there that reduce brain atrophy? AND TO THIS I will add. Due to the "Safety Issues" of the MAB's. In EU many would be far from the few locations where those require periodic tests could be preformed while patients are on the MAB's. To Brain Atrophy add our outstanding safety record and what do you have? Anavex 2-73.
John k9uwa
Keep the nothing burger at the forefront. Obviously, it's your job.
Your are telling there is multi trillion dollar market for this drug...great I am going to buy on Monday, hope it remain in this range till I get my fund wired.
IMO, more...
Many different disorders, neurodegenerative diseases, infectious diseases and severe injuries can cause brain atrophy, including:
Cerebral palsy.
Encephalitis.
HIV and AIDS.
Huntington’s disease.
Leukodystrophies.
Multiple sclerosis.
Stroke.
Syphilis.
Traumatic brain injury.
Alzheimer’s disease
That right there is worth a $15 billion Market Cap.
Great question. Anavex actually reported it as a Significant slowing of brain atrophy. During the Noble Capital Markets conference Dr Missling said as "the brain shrinks you have less memory". So clearly slowing brain shrinkage is tantamount to saving memory.
We attended a European AD conf recently, likely to that purpose. Our PDD trial a few years ago had European sites if I recall. Isn't much, I know.
I feel your pain.
I suspect that's right.
How many drugs are out there that reduce brain atrophy?
Should have been your first and primary point.
Thanks frrol, that's very valuable insight.
I can add that it's certainly not a done deal in Europe, for some of the reasons you give. I know the European regulatory situation very well, not specifically for AD. Broad KOL support is important and can really help in difficult situations. Not really needed for a breakthrough medicine with excellent data, but very needed here. If they don't approve it, it could seriously damage the company. If regulators have made up their minds, it's difficult to change, also for stupid ego reasons. Better to act proactively.
Should add that though it's the FDA relaxing its AD guidelines, there's a chance the EMA shares this view.
I met a PhD who does Alzheimer's research for a firm that consults for a few big pharmas, and her area includes amyloid beta oligomers. Most folks here know so little about the disease and pharma and assume that there are prejudicial camps in some kind of war of ideas. In reality, people like my acquaintance are scientists and they understand the complexity of AD. She's spent years learning what role AB plaques play in it. She explains incredibly complicated cellullar cascades, what is known about them, what is not known, the many theories, the failures, the progress. She explains that AB plaque removal is not a cure, even though this is her research area. The difference between serious scientists doing important work and unserious lay people speculating on a pet stock and seeing conspiracies.
Through me, she's familiar with the S1 receptor and Anavex, and thinks our approach might be therapeutic. She thinks other approaches might be as well, and that combo therapies will ultimately prove necessary. She explains that progress was made with the plaque and tangle MABs, and is optimistic that more progress lies ahead, in her area, our area, and others. Speaking with her, you understand how Anavex can be a worthwhile risk as a small investment. Other biotechs, too. She does not invest in any.
Her initial impression from our CTAD materials was that it wasn't "something a reputable biotech or pharma would release at a conference". I told her about our upcoming paper and EMA application and she said a paper is much needed, but with regulators she cautioned that our trial was still "really small" for AD.
I think Missling knows we have an uphill challenge in AD. He's laid out our regulatory approach, appealing to our: being a safe cheap pill, meeting the newly lowered endpoint guidelines, and having (albeit unorthodox) biomarker support. If there are no bad surprises in our paper, which will give us a clearer view into our little trial's outcomes, I think we have a chance at some contingent approvals. My biggest fear: what Missling called "ITT" is really an mITT that gives regulators pause, given our already small n. Fingers crossed there was no 'spin'.
I've been on vacation last few weeks, so I'm glad we don't have to wait much longer for the cases to be thrown out. You gave me crap when I said that on day one, but the bickering keeps it entertaining. ;)
Since you've been following, how did the various allegations consolidate to the lead plaintiff part?
Were both RETT and AD included? and what timeframes for the class?
On a side note, I recently added to $AVXL after salvaging what was left of my $ANVS position as my biotech hobby stock list continues to dwindle.
I do wish the $ANVS folks well and hope they can get some financing done with good PD results, but I think heavy dilution will keep their stock price muted.
Thank you. I understand some members are heavily bought into this and I'm hurting their baby. From my side it's difficult to see the stock going down while for me obvious next steps are not taken.
Why is that a Messianic complex?
The company clearly needs a partner for the large INDs and Missling acknowledged that early on. Keeping the rare diseases makes good sense. Those are much easier markets to address and have very high margins.
Thanks for sharing your thoughts. More information is always better. Some people are able to make their own determinations. Relax. There is a strong belief among the bull herd that manipulators have taken over this board. You'll likely get added to the 'Fudster' list and receive poop and rooster emoji's with each post. These can simply be taken as badges of courage when received from the anonymous internet board bullies.
I think holding Anavex to the politicking standards of Biogen and Lilly is a bit unrealistic. Anavex will ultimately let the regulatory decisions speak for themselves.
Blah Blah Blah. You don't like it hit the road
Yeah, and when a class action complaint alleges an opinion by a hack analyst, instead of alleging facts, you can tell right away they’ve likely got nothing.
"Fraudstein is the one who fed the case to an attorney" Absolutely NO QUESTION. I SAW it in MIDDLE MARCH popped up under "News" from my broker. KORSINSKY Our Bio Tech Journalist Adam Fartstain says... We are filing FRAUD charges against Missling and Anavex. See Stock Chart from about mid march through yesterday. Within a few days Other "Law Firms" piled on. I bet all of them had some non officer relative short the stock before the articles filing fraud came out and probably by now most of them have bought their way out of their short position.
Exactly Identical to the same process this same bunch did several years ago.
John k9uwa
Yes, I am late at this forum, but I have been at many neurology conferences for other indications), I have been following Anavex for about 2 years, among many other companies and different fora and with >20 years relevant experience. This is indeed how it works, competitors making the story about you and trying to undermine. Biogen and Lilly are strong in it and Anavex is not doing it in a clever way. Just naive and amateuristic, with a very few persons, Missling playing the brilliant mind, with no clue how it really works. Then indeed you may better give up and sell of.
Missling has always said partner large INDs and keep pediatric rare disease. Messianic complex.
It has been 2 year since AD possible pivotal trial was completed, but still no full data. Misleading using peer review cover to hide data and trial failure, he know as soon as he disclose full data, stock will tank to penny land in one trading day.
Rett, he was forced to disclose failure; otherwise, he would have used AUC end point
Pet word from those who are in the open to short and distort for profit! Psy Op...
“ And that the belief by the general market is very low.”
Typically the “belief” by the general market or another way is the “fair and balanced” market does not come into play until institutional ownership reaches 60% or OS shares. Good luck with waiting until that happens to give credit where credit is due.
“ The company is not present at medical meetings where the competition is all over the place, there are no activities,”
Again you come late persecuting our CEO not being aware of the years of Biogn bullying at the AAIC and other Alzheimer’s conferences with time slots overshadowing all he way until Biogens drug got, amazingly, approval. We all saw how that played and is playing out.
Your a very opinionated “ Johnnycomelately” and I think you are way off base.
What conspiracy theories are you referring to?
For WGT crowd everything is conspiracy theory, COO just left, he saw better opportunity and he simply left. not pushed out, no buy out, nothing, nada, zilch. For everything in Anavex land has very simple explanation, occam's razor, CEO is incompetent, and he has no desire to bring drug to market. His main goal is to run endless tiny trials and keep cruising with endless vacation in Europe, Greece.
The market doesn't believe Anavex doesn't have "any chance of success". Our share price reflects that most believe it has a low chance. You disagree (as do I). We are not the market; we're part of it.
You need to recognize risks. It will help your misunderstanding of securities markets and prevent the conspiracy theories. No hidden forces are out to hurt Anavex.
Followers
|
1064
|
Posters
|
|
Posts (Today)
|
14
|
Posts (Total)
|
458336
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |